New hope for severe colitis: Head-to-Head drug trial launches

NCT ID NCT07550673

First seen Apr 29, 2026 · Last updated May 14, 2026 · Updated 2 times

Summary

This study tests whether upadacitinib works as well as infliximab for people with a severe flare of ulcerative colitis who didn't get better with first-line treatment. About 226 adults will be randomly assigned to one of the two drugs and followed for 3 months. The goal is to see which drug controls symptoms faster and with fewer side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE SEVERE ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 3201 Hospital

    RECRUITING

    Hanzhong, Shaanxi, 710005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ankang Central Hospital

    RECRUITING

    Ankang, Shaanxi, 725000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shaanxi Provincial Nuclear Industry 215 Hospital

    RECRUITING

    Xianyang, Shaanxi, 712000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xijing Hosipital of Digestive Disease

    RECRUITING

    Xi'an, Shaanxi, 710005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.